§ 32.5(a)(6), which specifies certain disclosures to be made in connection with transactions in dealer options. The correction listed below should be made to that proposed rule.

FOR FURTHER INFORMATION CONTACT: R. Britt Lenz, Special Assistant to the Executive Director, Commodity Futures Trading Commission, 2033 K Street, N.W., Washington, D.C. 20581. Telephone (202) 254–7360.

CORRECTION: In FR Doc. 81–12547, which appeared in the April 27, 1981 issue of the Federal Register at page 23478, the Commodity Futures Trading Commission hereby corrects the first sentence of the boldfaced statement set forth in the proposed amendment to 17 CFR 32.5(a)(6) to read as follows:

PART 32—REGULATION OF COMMODITY OPTIONS TRANSACTIONS

§ 32.5 Disclosure.

(a) * * *

* * * * * *

(6) The following boldfaced statements on the first page of the summary disclosure statement:

BECAUSE OF THE VOLATILE NATURE OF THE COMMODITIES MARKETS, THE PURCHASE OF COMMODITY OPTIONS MAY NOT BE ADVISABLE FOR MANY MEMBERS OF THE PUBLIC. * * *

* * * * * *

Dated: April 30, 1981.

Jane K. Stuckey,

Secretary of the Commission.

[FR Doc. 81–13458 Filed 5–4–81; 8:45 am]

BILLING CODE 6351–01–M

---

17 CFR Part 32

Proposed Reissuance of and Amendments to Regulations Permitting the Grant, Offer and Sale of Options on Physical Commodities

Correction

In FR Doc. 81–12547, appearing at page 23469 in the issue for Monday, April 27, 1981, make the following correction:

On page 23477, in the middle column, the part heading "Part 32—Leverage Transactions" should have read "Part 32—Regulation of Commodity Option Transactions".

BILLING CODE 1505–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 351

[Docket No. 80N–0280]

Vaginal Contraceptive Drug Products for Over-the-Counter Human Use; Establishment of a Monograph: Extension of Time for Comments and Reply Comments

AGENCY: Food and Drug Administration.

ACTION: Establishment of a Monograph; Extension of comment periods.

SUMMARY: The Food and Drug Administration (FDA) extends to July 6, 1981, the comment period and to August 3, 1981 the reply comment period on the proposal to establish conditions for the safety, effectiveness, and labeling of over-the-counter (OTC) vaginal contraceptive drug products. This action is being taken in response to a request to allow more time for the collection and assessment of data to provide more meaningful comments on the issue.

DATES: Written comments by July 6, 1981, and reply comments by August 3, 1981.

ADDRESS: Written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: William E. Gilbertson, Bureau of Drugs (HFD–510), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4960.

SUPPLEMENTARY INFORMATION: In the Federal Register of December 12, 1980 (45 FR 82014), FDA proposed to establish conditions for the safety, effectiveness, and labeling of vaginal contraceptive drug products for over-the-counter (OTC) human use. The proposed rule, based on the recommendations of the Advisory Review Panel on OTC Contraceptive and Other Vaginal Drug Products, is part of the ongoing review of OTC drug products conducted by the agency. Interested persons were given until March 12, 1981 to comment on the proposal and until April 13, 1981 for reply comments. In response to the proposal, FDA has received a request for a 60-day extension of the comment period which is needed to present to FDA details concerning clinical testing techniques for the evaluation of these contraceptives.

FDA has carefully considered the request and believes that information described in he request may be of assistance to the agency in establishing the safety and effectiveness of OTC vaginal contraceptives. The agency considers a general extension of the comment period for 60 days from the date of this publication to be appropriate. Accordingly, the comment period for submissions by any interested person is extended to July 6, 1981, and the reply comment period is extended to August 3, 1981. Comments may be seen in the Dockets Management Branch, Food and Drug Administration, at the address noted above, between 9 a.m. and 4 p.m. Monday through Friday.

Dated: April 28, 1981.

William F. Randolph,

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 81–13412 Filed 5–4–81; 8:45 am]

BILLING CODE 4110–03–M

---

21 CFR Part 540

[Docket No. 81N–0072]

Iodometric Assay Method for Ampicillin and Amoxicillin

Correction

In FR Doc. 81–11569 appearing on page 22389 in the issue of Friday, April 17, 1981, on page 22392, second column, the section heading for § 540.107 should read as follows:

"§ 540.107e Ampicillin trihydrate boluses."

BILLING CODE 1501–01–M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Secretary

24 CFR Part 885

[Docket No. R–81–897]

Loans for Housing for the Elderly or Handicapped

AGENCY: Department of Housing and Urban Development.

ACTION: Notice of Congressional waiver request.

SUMMARY: Section 7(o)(4) of the Department of Housing and Urban Development Act permits the Secretary to request waiver of the legislation's requirements in appropriate instances. This Notice lists and briefly summarizes for public information a final rule relating to loans for housing for the elderly or handicapped with respect to which the Secretary is presently requesting waiver.